Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy

Purpose: To assess the efficacy and safety of adalimumab in elderly patients with noninfectious uveitis (NIU). Methods: An observational, retrospective, multicenter study was done. Changes in best-corrected visual acuity (BCVA), inflammatory activity parameters, central retinal thickness (CRT), and...

Full description

Saved in:

Bibliographic Details
Published in:	Ocular immunology and inflammation Vol. 29; no. 7-8; pp. 1591 - 1598
Main Authors:	Moll-Udina, Aina, Miguel Escuder, Lucía, Hernanz, Inés, Llorenç, Victor, Fonollosa, Alex, Cordero Coma, Miguel, Sainz de la Maza, Maite, Espinosa, Gerard, González Guijarro, J. Jacobo, Lopez Lopez, Fernando, Alba-Linero, Carmen, Hernández, Marisa, Martínez Costa, Lucía, Celdrán Vivancos, Diego, Giralt, Lena, Artaraz, Joseba, Soler Bartrina, Pablo, Jódar Márquez, Margarita, García de Vicuña, Rosario, Esquinas, Cristina, Adán, Alfredo
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis 17-11-2021
Subjects:	adalimumab Adalimumab - adverse effects Adalimumab - therapeutic use adverse events Aged efficacy elderly Female Follow-Up Studies Humans Male Middle Aged Retrospective Studies safety Treatment Outcome Tumor Necrosis Factor Inhibitors - adverse effects Tumor Necrosis Factor Inhibitors - therapeutic use uveitic macular edema Uveitis Uveitis - drug therapy Uveitis - physiopathology Visual Acuity - physiology uveitic macular edema elderly safety Uveitis adverse events adalimumab efficacy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Purpose: To assess the efficacy and safety of adalimumab in elderly patients with noninfectious uveitis (NIU). Methods: An observational, retrospective, multicenter study was done. Changes in best-corrected visual acuity (BCVA), inflammatory activity parameters, central retinal thickness (CRT), and the occurrence of adverse events (AE) developed during follow-up were recorded. Results: A total of 82 eyes from 41 patients 60 years of age and older with noninfectious uveitis treated with adalimumab were included. A significant improvement in BCVA (71.5 to 75.4 letters, p = .001) and in CRT (311.1 μm to 265 μm, p = .001) was observed. Moreover, a significant decrease from baseline in the rate of patients with anterior chamber cell (ACC) >0+ (34.6% to 5.7%, p = <0.001) or vitreous haze>0+ (21.3% to 4.3%, p = .002) was determined. AEs were observed in 11 patients (26.8%). Conclusion: Adalimumab can be safe and efficacious for the treatment of NIU in patients 60 years of age and older.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0927-3948 1744-5078
DOI:	10.1080/09273948.2020.1769139